Abstract

The health, economic, and social burden of neglected tropical diseases (NTDs) in Africa remains substantial, with elimination efforts hindered by persistent sociopolitical instability, including ongoing conflicts among political and ethnic groups that lead to internal displacement and migration. Here, we explore how innovative technologies can support Africa in addressing NTDs amidst such instability, through analysis of WHO and UNHCR data and a systematic literature review. Countries in Africa facing sociopolitical instability also bear a high burden of NTDs, with the continent ranking second globally in NTD burden (33%, 578 million people) and first in internal displacement (50%, 31.6 million people) in 2023. Studies have investigated technologies for their potential in NTD prevention, surveillance, diagnosis, treatment and management. Integrating the evidence, we discuss nine promising technologies—artificial intelligence, drones, mobile clinics, nanotechnology, telemedicine, augmented reality, advanced point-of-care diagnostics, mobile health Apps, and wearable sensors—that could enhance Africa’s response to NTDs in the face of persistent sociopolitical instability. As stability returns, these technologies will evolve to support more comprehensive and sustainable health development. The global health community should facilitate deployment of health technologies to those in greatest need to help achieve the NTD 2030 Roadmap and other global health targets.

Countries in Africa facing sociopolitical instability also bear a high burden of neglected tropical diseases (NTDs). Here, the authors explore the potential of health technologies to address NTDs through a systematic literature review.

Details

Title
Innovative technologies to address neglected tropical diseases in African settings with persistent sociopolitical instability
Author
Manyazewal, Tsegahun 1   VIAFID ORCID Logo  ; Davey, Gail 2 ; Hanlon, Charlotte 3 ; Newport, Melanie J. 4   VIAFID ORCID Logo  ; Hopkins, Michael 5 ; Wilburn, Jenni 4 ; Bakhiet, Sahar 6 ; Mutesa, Leon 7   VIAFID ORCID Logo  ; Semahegn, Agumasie 8 ; Assefa, Esubalew 9 ; Fekadu, Abebaw 10   VIAFID ORCID Logo 

 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688) 
 Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X); Addis Ababa University, School of Public Health, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688) 
 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); King’s College London, Centre for Global Mental Health, Health Services and Population Research Department, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); Addis Ababa University, Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688) 
 Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X) 
 University of Sussex, Science Policy Research Unit, Brighton, UK (GRID:grid.12082.39) (ISNI:0000 0004 1936 7590) 
 University of Khartoum, Institute of Endemic Diseases, Khartoum, Sudan (GRID:grid.9763.b) (ISNI:0000 0001 0674 6207) 
 University of Rwanda, Center for Human Genetics, College of Medicine and Health Sciences, Kigali, Rwanda (GRID:grid.10818.30) (ISNI:0000 0004 0620 2260) 
 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Haramaya University, College of Health and Medical Sciences, Harar, Ethiopia (GRID:grid.192267.9) (ISNI:0000 0001 0108 7468) 
 Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Queen Mary University of London, Health Economics and Policy Research Unit, Wolfson Institute of Population Health, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
10  Addis Ababa University, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688); Brighton and Sussex Medical School, Centre for Global Health Research, Brighton, UK (GRID:grid.414601.6) (ISNI:0000 0000 8853 076X); Addis Ababa University, Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity-Building, School of Medicine, College of Health Sciences, Addis Ababa, Ethiopia (GRID:grid.7123.7) (ISNI:0000 0001 1250 5688) 
Pages
10274
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3133603548
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.